Eurogin 2016 Roadmap

how HPV knowledge is changing screening practice

Nicolas Wentzensen, Marc Arbyn, Johannes Berkhof, Mark Bower, Karen Canfell, Mark Einstein, Christopher Farley, Joseph Monsonego, Silvia Franceschi

Research output: Contribution to journalReview article

43 Citations (Scopus)

Abstract

Human papillomaviruses (HPVs) are the necessary cause of most cervical cancers, a large proportion of other anogenital cancers, and a subset of oropharyngeal cancers. The knowledge about HPV has led to development of novel HPV-based prevention strategies with important impact on clinical and public health practice. Two complementary reviews have been prepared following the 2015 Eurogin Conference to evaluate how knowledge about HPV is changing practice in HPV infection and disease control through vaccination and screening. This review focuses on screening for cervical and anal cancers in increasingly vaccinated populations. The introduction of HPV vaccines a decade ago has led to reductions in HPV infections and early cancer precursors in countries with wide vaccination coverage. Despite the high efficacy of HPV vaccines, cervical cancer screening will remain important for many decades. Many healthcare systems are considering switching to primary HPV screening, which has higher sensitivity for cervical precancers and allows extending screening intervals. We describe different approaches to implementing HPV-based screening efforts in different healthcare systems with a focus in high-income countries. While the population prevalence for other anogenital cancers is too low for population-based screening, anal cancer incidence is very high in HIV-infected men who have sex with men, warranting consideration of early detection approaches. We summarize the current evidence on HPV-based prevention of anal cancers and highlight important evidence gaps.

Original languageEnglish (US)
Pages (from-to)2192-2200
Number of pages9
JournalInternational Journal of Cancer
Volume140
Issue number10
DOIs
StatePublished - May 15 2017

Fingerprint

Anus Neoplasms
Uterine Cervical Neoplasms
Papillomavirus Vaccines
Papillomavirus Infections
Vaccination
Population
Oropharyngeal Neoplasms
Public Health Practice
Delivery of Health Care
Neoplasms
Human Development
Infection Control
Early Detection of Cancer
HIV
Incidence

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Keywords

  • HPV
  • anal cancer
  • cervical cancer
  • cytology
  • screening
  • vaccination

Cite this

Wentzensen, N., Arbyn, M., Berkhof, J., Bower, M., Canfell, K., Einstein, M., ... Franceschi, S. (2017). Eurogin 2016 Roadmap: how HPV knowledge is changing screening practice. International Journal of Cancer, 140(10), 2192-2200. https://doi.org/10.1002/ijc.30579
Wentzensen, Nicolas ; Arbyn, Marc ; Berkhof, Johannes ; Bower, Mark ; Canfell, Karen ; Einstein, Mark ; Farley, Christopher ; Monsonego, Joseph ; Franceschi, Silvia. / Eurogin 2016 Roadmap : how HPV knowledge is changing screening practice. In: International Journal of Cancer. 2017 ; Vol. 140, No. 10. pp. 2192-2200.
@article{eb812ea0b7cc48648786bd702a187e46,
title = "Eurogin 2016 Roadmap: how HPV knowledge is changing screening practice",
abstract = "Human papillomaviruses (HPVs) are the necessary cause of most cervical cancers, a large proportion of other anogenital cancers, and a subset of oropharyngeal cancers. The knowledge about HPV has led to development of novel HPV-based prevention strategies with important impact on clinical and public health practice. Two complementary reviews have been prepared following the 2015 Eurogin Conference to evaluate how knowledge about HPV is changing practice in HPV infection and disease control through vaccination and screening. This review focuses on screening for cervical and anal cancers in increasingly vaccinated populations. The introduction of HPV vaccines a decade ago has led to reductions in HPV infections and early cancer precursors in countries with wide vaccination coverage. Despite the high efficacy of HPV vaccines, cervical cancer screening will remain important for many decades. Many healthcare systems are considering switching to primary HPV screening, which has higher sensitivity for cervical precancers and allows extending screening intervals. We describe different approaches to implementing HPV-based screening efforts in different healthcare systems with a focus in high-income countries. While the population prevalence for other anogenital cancers is too low for population-based screening, anal cancer incidence is very high in HIV-infected men who have sex with men, warranting consideration of early detection approaches. We summarize the current evidence on HPV-based prevention of anal cancers and highlight important evidence gaps.",
keywords = "HPV, anal cancer, cervical cancer, cytology, screening, vaccination",
author = "Nicolas Wentzensen and Marc Arbyn and Johannes Berkhof and Mark Bower and Karen Canfell and Mark Einstein and Christopher Farley and Joseph Monsonego and Silvia Franceschi",
year = "2017",
month = "5",
day = "15",
doi = "10.1002/ijc.30579",
language = "English (US)",
volume = "140",
pages = "2192--2200",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "10",

}

Wentzensen, N, Arbyn, M, Berkhof, J, Bower, M, Canfell, K, Einstein, M, Farley, C, Monsonego, J & Franceschi, S 2017, 'Eurogin 2016 Roadmap: how HPV knowledge is changing screening practice', International Journal of Cancer, vol. 140, no. 10, pp. 2192-2200. https://doi.org/10.1002/ijc.30579

Eurogin 2016 Roadmap : how HPV knowledge is changing screening practice. / Wentzensen, Nicolas; Arbyn, Marc; Berkhof, Johannes; Bower, Mark; Canfell, Karen; Einstein, Mark; Farley, Christopher; Monsonego, Joseph; Franceschi, Silvia.

In: International Journal of Cancer, Vol. 140, No. 10, 15.05.2017, p. 2192-2200.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Eurogin 2016 Roadmap

T2 - how HPV knowledge is changing screening practice

AU - Wentzensen, Nicolas

AU - Arbyn, Marc

AU - Berkhof, Johannes

AU - Bower, Mark

AU - Canfell, Karen

AU - Einstein, Mark

AU - Farley, Christopher

AU - Monsonego, Joseph

AU - Franceschi, Silvia

PY - 2017/5/15

Y1 - 2017/5/15

N2 - Human papillomaviruses (HPVs) are the necessary cause of most cervical cancers, a large proportion of other anogenital cancers, and a subset of oropharyngeal cancers. The knowledge about HPV has led to development of novel HPV-based prevention strategies with important impact on clinical and public health practice. Two complementary reviews have been prepared following the 2015 Eurogin Conference to evaluate how knowledge about HPV is changing practice in HPV infection and disease control through vaccination and screening. This review focuses on screening for cervical and anal cancers in increasingly vaccinated populations. The introduction of HPV vaccines a decade ago has led to reductions in HPV infections and early cancer precursors in countries with wide vaccination coverage. Despite the high efficacy of HPV vaccines, cervical cancer screening will remain important for many decades. Many healthcare systems are considering switching to primary HPV screening, which has higher sensitivity for cervical precancers and allows extending screening intervals. We describe different approaches to implementing HPV-based screening efforts in different healthcare systems with a focus in high-income countries. While the population prevalence for other anogenital cancers is too low for population-based screening, anal cancer incidence is very high in HIV-infected men who have sex with men, warranting consideration of early detection approaches. We summarize the current evidence on HPV-based prevention of anal cancers and highlight important evidence gaps.

AB - Human papillomaviruses (HPVs) are the necessary cause of most cervical cancers, a large proportion of other anogenital cancers, and a subset of oropharyngeal cancers. The knowledge about HPV has led to development of novel HPV-based prevention strategies with important impact on clinical and public health practice. Two complementary reviews have been prepared following the 2015 Eurogin Conference to evaluate how knowledge about HPV is changing practice in HPV infection and disease control through vaccination and screening. This review focuses on screening for cervical and anal cancers in increasingly vaccinated populations. The introduction of HPV vaccines a decade ago has led to reductions in HPV infections and early cancer precursors in countries with wide vaccination coverage. Despite the high efficacy of HPV vaccines, cervical cancer screening will remain important for many decades. Many healthcare systems are considering switching to primary HPV screening, which has higher sensitivity for cervical precancers and allows extending screening intervals. We describe different approaches to implementing HPV-based screening efforts in different healthcare systems with a focus in high-income countries. While the population prevalence for other anogenital cancers is too low for population-based screening, anal cancer incidence is very high in HIV-infected men who have sex with men, warranting consideration of early detection approaches. We summarize the current evidence on HPV-based prevention of anal cancers and highlight important evidence gaps.

KW - HPV

KW - anal cancer

KW - cervical cancer

KW - cytology

KW - screening

KW - vaccination

UR - http://www.scopus.com/inward/record.url?scp=85010611226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010611226&partnerID=8YFLogxK

U2 - 10.1002/ijc.30579

DO - 10.1002/ijc.30579

M3 - Review article

VL - 140

SP - 2192

EP - 2200

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 10

ER -